세계의 정신분열증 치료제 시장 - 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Global Schizophrenia Drugs Market will record a 7.1% CAGR from 2024 to 2032, attributed to an increase in the prevalence of schizophrenia, which necessitates effective treatment solutions. Advances in pharmacological research have led to the development of novel antipsychotic medications with improved efficacy and reduced side effects, making treatment more manageable and enhancing patient adherence. Citing an instance, in April 2023, CHEPLAPHARM announced the acquisition of Zyprexa(R) from Eli Lilly. The deal includes global rights to Zyprexa(R) and its various forms, enhancing CHEPLAPHARM's portfolio for schizophrenia and bipolar disorders treatment.

Additionally, growing awareness and de-stigmatization of mental health conditions are leading to higher diagnosis rates and greater demand for treatment options. The rise in healthcare expenditure and investment in mental health infrastructure further supports market expansion by facilitating access to innovative therapies and comprehensive care.

The schizophrenia drugs market is sorted based on therapeutic class, type, treatment, distribution channel, and region.

The third-generation antipsychotics segment will retain a notable demand from 2024 through 2032, because of their superior efficacy and favorable side effect profile compared to earlier classes of antipsychotics. These newer medications, also known as atypical antipsychotics, offer significant advantages such as reduced risk of extrapyramidal symptoms and lower incidence of weight gain and metabolic issues. Their ability to manage both positive and negative symptoms of schizophrenia more effectively, combined with improved patient adherence and quality of life, is ushering in the adoption of schizophrenia drugs.

By 2032, the hebephrenic schizophrenia segment will hold a remarkable market share, due to its unique and often severe symptomatology, which necessitates specialized treatment approaches. Characterized by disorganized behavior, inappropriate emotional responses, and impaired cognitive function, hebephrenic schizophrenia presents distinct challenges in management. The need for effective medications that address these specific symptoms is fueling the development and adoption of new drug therapies, aiding the market expansion.

North America schizophrenia drugs market will register a noteworthy growth rate between 2024 and 2032, propelled by a high prevalence of schizophrenia and amplified demand for effective treatment solutions. Advanced healthcare infrastructure and widespread access to medical services facilitate early diagnosis and treatment, further supporting market growth. Additionally, increasing awareness and reducing stigma around mental health conditions encourage more individuals to seek treatment, contributing to the rising demand for schizophrenia drugs across North America.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of schizophrenia
    • 3.2.1.2 Advancements in drug delivery systems
    • 3.2.1.3 Government initiatives and support
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects of drugs
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Pipeline analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapeutic Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Second generation antipsychotics
• 5.3 Third generation antipsychotics
• 5.4 Other therapeutic classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Paranoid schizophrenia
• 6.3 Hebephrenic schizophrenia
• 6.4 Catatonic schizophrenia
• 6.5 Undifferentiated schizophrenia
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Alkermes Public Limited Company
• 10.3 AstraZeneca PLC
• 10.4 Bristol-Myers Squibb Company
• 10.5 Eli Lilly and Company
• 10.6 H. Lundbeck A/S
• 10.7 Intra-Cellular Therapies, Inc.
• 10.8 Johnson and Johnson
• 10.9 Otsuka Pharmaceutical Co., Ltd.
• 10.10 Pfizer Inc.
• 10.11 Recordati Industria Chimica e Farmaceutica S.p.A
• 10.12 SUMITOMO PHARMA CO., LTD
• 10.13 Takeda Pharmaceutical Company Limited
• 10.14 Teva Pharmaceutical Industries Limited
• 10.15 Vanda Pharmaceuticals Inc.